Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and nemonoxacin

moxifloxacin has been researched along with nemonoxacin in 5 studies

Compound Research Comparison

Studies
(moxifloxacin)		Trials
(moxifloxacin)		Recent Studies (post-2010)
(moxifloxacin)		Studies
(nemonoxacin)		Trials
(nemonoxacin)		Recent Studies (post-2010) (nemonoxacin)
3,1575521,690401530

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Adam, HJ; Hoban, DJ; King, CR; Laing, NM; Lulashnyk, B; Zhanel, GG1
Chen, HC; King, CH; Lai, JF; Lauderdale, TL; Shiau, YR1
Hsueh, PR; Lee, PI; Yang, JC1
Chi, Z; Pan, X; Tang, W; Yin, Y; Zhao, M1
Chen, Y; Li, Z; Meng, W; Xiong, R; Zeng, H; Zhao, Z1

Other Studies

5 other study(ies) available for moxifloxacin and nemonoxacin

ArticleYear
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:11

    Topics: Anti-Infective Agents; Bacteria; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Quinolones

2009
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:3

    Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Quinolones; Taiwan

2010
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2010, Volume: 29, Issue:11

    Topics: Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clarithromycin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gemifloxacin; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Sequence Analysis, Protein; Taiwan; Tetracyclines; Tigecycline

2010
Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis.
    International journal of environmental research and public health, 2022, 04-15, Volume: 19, Issue:8

    Topics: Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Analysis; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Pneumonia; Quinolones; Randomized Controlled Trials as Topic; Tuberculosis, Pulmonary

2022
Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease.
    Scientific reports, 2023, 10-07, Volume: 13, Issue:1

    Topics: Anti-Bacterial Agents; Disease Progression; Humans; Moxifloxacin; Outpatients; Pulmonary Disease, Chronic Obstructive

2023